Related Subjects:
| Metabolic Acidosis
| Aspirin or Salicylate Toxicity
| Ethylene Glycol Toxicity
| Renal Tubular Acidosis
| Lactic Acidosis
โ ๏ธ FDA guidance: Fomepizole is indicated if methanol or ethylene glycol levels โฅ20 mg/dL or ingestion is suspected with a compatible high anion gap metabolic acidosis.
If ethylene glycol โฅ50 mg/dL, or the patient has renal failure or worsening acidosis, haemodialysis should also be initiated.
๐ก Remember: haemodialysis removes fomepizole โ doses must therefore be given more frequently during dialysis.
๐ About
- Fomepizole (4-methylpyrazole, 4-MP) is a potent competitive inhibitor of alcohol dehydrogenase.
- It prevents the metabolism of methanol and ethylene glycol into their toxic organic acid metabolites (formic acid and glycolic/oxalic acids).
- Used in place of ethanol, which acts by the same mechanism but is harder to titrate, more toxic, and less predictable.
- Management advice should be sought from the National Poisons Information Service (NPIS) or TOXBASE.
โ๏ธ Mode of Action
- Both methanol and ethylene glycol themselves are relatively non-toxic.
- Toxicity occurs after hepatic alcohol dehydrogenase converts them to formic acid (causing optic and CNS injury) or glycolic/oxalic acids (causing renal failure).
- Fomepizole acts as a competitive substrate for alcohol dehydrogenase, blocking this first metabolic step and allowing the parent alcohol to be excreted unchanged.
- Inhibition is rapid, sustained, and predictable; fomepizole is renally excreted.
๐ฏ Indications
- Suspected or confirmed methanol or ethylene glycol poisoning with any of the following:
- Plasma level โฅ20 mg/dL (3.2 mmol/L)
- High anion gap metabolic acidosis (anion gap >16 mmol/L) unexplained by other causes
- Osmolar gap >10โ15 mOsm/kg with history of ingestion
- Visual disturbance (methanol) or renal impairment (ethylene glycol)
๐ Dose (for both Methanol and Ethylene Glycol Poisoning)
- Loading dose: Fomepizole 15 mg/kg IV diluted in โฅ100 mL of 0.9% NaCl or 5% dextrose, infused over 30 min.
- Maintenance:
- 10 mg/kg IV every 12 h for 4 doses, then
- Increase to 15 mg/kg IV every 12 h thereafter.
- Continue until:
- Serum methanol or ethylene glycol <20 mg/dL
- pH normalised
- Patient clinically recovered
- โ ๏ธ During haemodialysis: Fomepizole is dialysable.
Give the same dose every 4 h during dialysis, then revert to 12-hourly once dialysis stops.
๐ง Pathophysiological Rationale
- Methanol: Metabolised โ formaldehyde โ formic acid โ inhibits mitochondrial cytochrome oxidase โ severe lactic acidosis + optic nerve injury โ blindness.
- Ethylene glycol: Metabolised โ glycolic โ oxalic acid โ binds calcium โ renal tubular deposition of calcium oxalate crystals โ renal failure + hypocalcaemia.
- Fomepizole halts this chain reaction early โ the sooner itโs given, the less organ injury occurs.
๐งฉ Adjunctive and Supportive Management
- Correct metabolic acidosis with IV bicarbonate as indicated.
- Consider folinic acid (leucovorin) 50 mg IV 4-hourly for methanol toxicity (enhances formate metabolism).
- Consider thiamine (100 mg IV) and pyridoxine (50 mg IV) for ethylene glycol toxicity (enhance non-toxic metabolism).
- Initiate haemodialysis if:
- pH <7.25 or severe acidosis refractory to bicarbonate
- Renal failure (oliguria/anuria, creatinine rising)
- Visual impairment or coma
- Serum methanol/ethylene glycol >50 mg/dL
๐ Interactions
- No major pharmacological interactions, but avoid concurrent ethanol therapy โ both act on alcohol dehydrogenase and may compete unpredictably.
- Monitor liver enzymes if combined with hepatotoxic drugs.
๐ซ Contraindications
- Known hypersensitivity to fomepizole or pyrazoles.
- Use with caution in pregnancy โ riskโbenefit should favour maternal survival.
โ ๏ธ Side Effects
- Injection-site venous irritation if undiluted (use โฅ100 mL diluent).
- Headache, dizziness, nausea, mild drowsiness.
- Transient rash or eosinophilia.
- Occasional transient โ transaminases.
๐งฎ Differential: Fomepizole vs Ethanol
| Characteristic |
Fomepizole |
Ethanol |
| Mechanism |
Direct competitive inhibition of alcohol dehydrogenase |
Acts as preferred substrate for alcohol dehydrogenase |
| Predictability |
Linear kinetics, predictable |
Variable kinetics; frequent monitoring required |
| Administration |
IV bolus/infusion |
IV or oral (ethanol 10%) |
| Side effects |
Minimal |
Hypoglycaemia, intoxication, sedation |
| Cost |
Very high |
Cheap |
๐ References